Before switching to a new molecular testing platform for C. difficile, what should the IP review with laboratory leadership?

• A. Turnaround time only
• B. The cost only
• C. Both the sensitivity and susceptibility of the testing platform
• D. Training requirements only

Answer: (C)

Understanding how well a new molecular test detects C. difficile is essential before switching platforms. The most important factor to review with laboratory leadership is how accurately the test identifies patients—specifically its sensitivity and specificity. Sensitivity tells you how good the test is at catching true positive cases, so you minimize missing infected patients who could transmit the organism. Specificity tells you how well the test avoids false positives, which is crucial to prevent unnecessary isolation, treatment, and misallocation of resources. These performance characteristics directly drive infection prevention decisions, patient safety, and how the lab will impact the clinical workflow. While turnaround time, cost, and training are important considerations, they don’t by themselves guarantee safe and effective patient management unless the test reliably detects true positives and true negatives.